New York State Teachers Retirement System Sells 39,154 Shares of AbbVie Inc. $ABBV

Key Points

• New York State Teachers Retirement System trimmed its position in AbbVie by 2.6%, selling 39,154 shares and leaving it with 1,441,063 shares (about 0.08% of AbbVie), making ABBV its 18th‑largest holding.
• AbbVie reported Q1 EPS of $2.65 (missing the $3.01 estimate) but revenue beat at $15.0B and management raised 2026 adjusted EPS guidance to $14.08–$14.28; the stock rallied roughly 4.9% and Bank of America upgraded the name to Buy.
• Several corporate insiders have sold shares recently—SVP David Ryan Purdue sold 5,230 shares and EVP Perry C. Siatis sold 22,381 shares—leaving insiders with only about 0.06% ownership.

New York State Teachers Retirement System trimmed its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 2.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,441,063 shares of the company's stock after selling 39,154 shares during the period. AbbVie makes up approximately 0.6% of New York State Teachers Retirement System's portfolio, making the stock its 18th biggest position. New York State Teachers Retirement System owned approximately 0.08% of AbbVie worth $329,268,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ABBV. Wellington Management Group LLP increased its position in AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock valued at $2,439,714,000 after buying an additional 8,646,424 shares in the last quarter. Vanguard Group Inc. increased its holdings in AbbVie by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company's stock worth $41,306,353,000 after purchasing an additional 3,032,438 shares in the last quarter. Raymond James Financial Inc. increased its holdings in AbbVie by 41.8% during the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company's stock worth $1,733,222,000 after purchasing an additional 2,753,312 shares in the last quarter. Alliancebernstein L.P. increased its holdings in AbbVie by 31.8% during the 3rd quarter. Alliancebernstein L.P. now owns 7,281,327 shares of the company's stock worth $1,685,918,000 after purchasing an additional 1,758,657 shares in the last quarter. Finally, Amundi increased its holdings in AbbVie by 15.6% during the 3rd quarter. Amundi now owns 10,508,317 shares of the company's stock worth $2,418,909,000 after purchasing an additional 1,414,621 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

Insider Activity at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares of the company's stock, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the company's stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares of the company's stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.06% of the company's stock.

AbbVie Trading Up 4.9%

Shares of ABBV stock traded up $9.92 during trading on Thursday, hitting $213.81. The company's stock had a trading volume of 2,486,347 shares, compared to its average volume of 7,138,852. The company has a market cap of $378.06 billion, a PE ratio of 90.79, a P/E/G ratio of 0.71 and a beta of 0.38. The business has a fifty day moving average of $214.80 and a 200-day moving average of $221.67. AbbVie Inc. has a 52 week low of $176.57 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.01 by ($0.36). The business had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business's revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the company earned $2.46 earnings per share. As a group, research analysts predict that AbbVie Inc. will post 14.21 EPS for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. AbbVie's dividend payout ratio is currently 293.22%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 results: Revenue of $15.00B beat consensus and AbbVie raised 2026 adjusted EPS guidance to $14.08–$14.28, citing Skyrizi/Rinvoq strength. AbbVie Reports First-Quarter 2026 Financial Results
• Positive Sentiment: Bank of America upgraded ABBV from Neutral to Buy and set a $234 price target, supporting upside vs. current levels.
• Positive Sentiment: Regulatory progress: AbbVie submitted FDA applications/label-expansion filings for Rinvoq (upadacitinib) in alopecia areata and other indications — potential sales tailwind if approved. AbbVie Submits Application to FDA for Upadacitinib
• Positive Sentiment: Pipeline/BD: AbbVie holds an option/warrant around Kestrel (KRAS program) that could lead to up to $1.45B in deal value and expands oncology exposure. AbbVie sinks talons into KRAS with right to buy Kestrel
• Positive Sentiment: Partner milestone: EvolveImmune nomination triggered an $18M milestone payment tied to its AbbVie collaboration — near‑term non‑core cash positive. EvolveImmune Therapeutics Announces Achievement
• Neutral Sentiment: Allergan Aesthetics (AbbVie unit) launched a May philanthropic campaign via Allē — positive PR but limited direct financial impact. Allergan Aesthetics Launches Philanthropic Effort
• Neutral Sentiment: Valuation commentary: Several analyst pieces are re‑assessing AbbVie after recent price weakness; useful for longer‑term investors but not an immediate catalyst. Assessing AbbVie Valuation
• Negative Sentiment: Analyst revisions: Erste Group trimmed FY2026/FY2027 EPS estimates modestly (small downward revisions) — a warning that some sell‑side forecasts are being re‑tuned.
• Negative Sentiment: Legacy declines: Humira and Imbruvica continue to contract; though newer immunology and neuroscience products offset much of the decline, legacy erosion remains a structural headwind. AbbVie tops quarterly expectations

Analyst Upgrades and Downgrades

A number of brokerages have commented on ABBV. Sanford C. Bernstein reissued a "market perform" rating on shares of AbbVie in a report on Thursday, February 5th. Wall Street Zen lowered AbbVie from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 11th. Weiss Ratings reissued a "hold (c)" rating on shares of AbbVie in a report on Wednesday, January 21st. UBS Group decreased their price objective on AbbVie from $240.00 to $230.00 and set a "neutral" rating for the company in a report on Thursday, February 5th. Finally, Piper Sandler decreased their price objective on AbbVie from $299.00 to $294.00 and set an "overweight" rating for the company in a report on Thursday, April 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $252.38.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.